Daiken Medical Co., Ltd. (TYO:7775)
Japan · Delayed Price · Currency is JPY 421.00
+1.00 (0.24%)
Aug 5, 2026, 3:30 PM JST
Daiken Medical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 10,232 | 10,290 | 9,951 | 9,750 | 9,137 | 8,540 | |
Revenue Growth | 1.77% | 3.41% | 2.06% | 6.71% | 6.99% | 8.64% |
Cost of Revenue | 6,376 | 6,340 | 5,855 | 5,768 | 5,607 | 4,856 |
Gross Profit | 3,855 | 3,950 | 4,096 | 3,982 | 3,530 | 3,684 |
Selling, General & Admin | 2,233 | 2,260 | 2,209 | 2,240 | 2,105 | 2,092 |
Research & Development | 368 | 368 | 332 | 249 | 316 | 382 |
Operating Expenses | 2,646 | 2,673 | 2,584 | 2,539 | 2,475 | 2,533 |
Operating Income | 1,209 | 1,277 | 1,512 | 1,443 | 1,055 | 1,151 |
Interest Expense | -14.17 | -12 | -9 | -4 | -3 | -3 |
Interest & Investment Income | 2 | 1 | - | - | - | - |
Currency Exchange Gain (Loss) | 0.69 | 2 | - | 2 | - | 1 |
Other Non Operating Income (Expenses) | 6.33 | 5 | 6 | 5 | - | 3 |
EBT Excluding Unusual Items | 1,204 | 1,273 | 1,509 | 1,446 | 1,052 | 1,152 |
Gain (Loss) on Sale of Assets | - | - | - | 2 | - | - |
Asset Writedown | -28 | -28 | -2 | -5 | -28 | -1 |
Other Unusual Items | -0.33 | - | - | -8 | - | - |
Pretax Income | 1,175 | 1,245 | 1,507 | 1,435 | 1,024 | 1,151 |
Income Tax Expense | 301.44 | 323 | 410 | 447 | 312 | 320 |
Net Income | 873.49 | 922 | 1,097 | 988 | 712 | 831 |
Net Income to Common | 873.49 | 922 | 1,097 | 988 | 712 | 831 |
Net Income Growth | -14.66% | -15.95% | 11.03% | 38.76% | -14.32% | 23.11% |
Shares Outstanding (Basic) | 29 | 29 | 29 | 29 | 29 | 29 |
Shares Outstanding (Diluted) | 29 | 29 | 29 | 29 | 29 | 29 |
Shares Change | - | - | - | - | - | - |
EPS (Basic) | 30.40 | 32.09 | 38.19 | 34.39 | 24.78 | 28.93 |
EPS (Diluted) | 30.40 | 32.09 | 38.19 | 34.39 | 24.78 | 28.93 |
EPS Growth | -14.66% | -15.95% | 11.03% | 38.76% | -14.32% | 23.11% |
Free Cash Flow | - | 240 | 954 | 1,393 | 791 | 931 |
Free Cash Flow Per Share | - | 8.35 | 33.21 | 48.49 | 27.53 | 32.41 |
Gross Margin | 37.68% | 38.39% | 41.16% | 40.84% | 38.63% | 43.14% |
Operating Margin | 11.82% | 12.41% | 15.19% | 14.80% | 11.55% | 13.48% |
Profit Margin | 8.54% | 8.96% | 11.02% | 10.13% | 7.79% | 9.73% |
Free Cash Flow Margin | - | 2.33% | 9.59% | 14.29% | 8.66% | 10.90% |
EBITDA | 1,474 | 1,535 | 1,744 | 1,657 | 1,322 | 1,465 |
EBITDA Margin | 14.40% | 14.92% | 17.53% | 16.99% | 14.47% | 17.15% |
D&A For EBITDA | 264.5 | 258 | 232 | 214 | 267 | 314 |
EBIT | 1,209 | 1,277 | 1,512 | 1,443 | 1,055 | 1,151 |
EBIT Margin | 11.82% | 12.41% | 15.19% | 14.80% | 11.55% | 13.48% |
Effective Tax Rate | 25.66% | 25.94% | 27.21% | 31.15% | 30.47% | 27.80% |